Brief: X4 Pharmaceuticals Announces FDA Approval Of Xolremdi Capsules, First Drug Indicated In Patients With Whim Syndrome
29/04/2024 12:15
April 29 (Reuters) - X4 Pharmaceuticals Inc XFOR.O :
* X4 PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF XOLREMDI™
(MAVORIXAFOR) CAPSULES, FIRST DRUG INDICATED IN PATIENTS WITH
WHIM SYNDROME
Source text for Eikon: ID:nGNX1fkj3K
Further company coverage: XFOR.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on X4 Pharmaceuticals
See all newsBrief: X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
X4 Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: X4 Pharmaceuticals Q2 Operating Expenses USD 25.197 Million
X4 Pharmaceuticals Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule